Pharmacologic Treatment of Paraphilias

Psychiatric Clinics of North America

Volumn 37, Issue 2, 2014, Pages 173-181

  Assumpção, Alessandra Almeida ^a   Garcia, Frederico Duarte ^a,b   Garcia, Heloise Delavenne ^a,b   Bradford, John M W ^c   Thibaut, Florence ^d,e,f  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Psychiatry and Addictive Disorders University Hospital Cochin Tarnier ^*  (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSERM   (France)

Author keywords

Cyproterone acetate; Gonadotropin releasing hormone analogue; Medroxyprogesterone acetate; Paraphilia; Pedophilia; Selective serotonin reuptake inhibitor; Sex offender

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TRIPTORELIN; ANTIDEPRESSANT AGENT; GONADORELIN;

BEHAVIOR THERAPY; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COGNITIVE THERAPY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DSM-5; DSM-IV-TR; ENDOCRINE DISEASE; EXHIBITIONISM DISORDER; FETISHISM DISORDER; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PARAPHILIC DISORDER; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PEDOPHILIA DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL BEHAVIOR; SEXUAL CRIME; SEXUAL DEVIATION; SEXUAL VIOLENCE; TREATMENT DURATION; VOYEURISM DISORDER; AGONISTS; ANALOGS AND DERIVATIVES; DRUG THERAPY;

ANDROGEN ANTAGONISTS; ANTIDEPRESSIVE AGENTS; CYPROTERONE ACETATE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MEDROXYPROGESTERONE ACETATE; PARAPHILIAS; SEROTONIN UPTAKE INHIBITORS; TRIPTORELIN PAMOATE;

EID: 84901486392     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2014.03.002     Document Type: Review

References (35)

1. Garcia F.D., Thibaut F. Current concepts in the pharmacotherapy of paraphilias. Drugs 2011, 71(6):771-790.
2. Marshall P. The prevalence of convictions for sexual offending 1997, vol. 55. Great Britain Home Office Research Development and Statistics Directorate, London.
3. Turner D., Basdekis-Jozsa R., Briken P. Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions. JSex Med 2013, 10(2):570-578.
4. Post L.A., Mezey N.J., Maxwell C., et al. The rape tax tangible and intangible costs of sexual violence. JInterpers Violence 2002, 17(7):773-782.
5. Hanson R.K., Karl R., Harris A.J., Canada CSpepc La récidive sexuelle: d'une simplicité trompeuse 2004, Sécurité publique et protection civile, Ottawa, Canada.
6. Hanson R.K., Morton-Bourgon K.E. The characteristics of persistent sexual offenders: a meta-analysis of recidivism studies. JConsult Clin Psychol 2005, 73(6):1154.
7. Garcia F.D., Delavenne H.G., Assumpção Ade F.A., et al. Pharmacologic treatment of sex offenders with paraphilic disorder. Curr Psychiatry Rep 2013, 15(5):1-6.
8. Thibaut F., Barra F.D., Gordon H., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry 2010, 11(4):604-655.
9. Garcia F.D., Thibaut F. Sexual addictions. Am J Drug Alcohol Abuse 2010, 36(5):254-260.
10. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
11. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM V 2013, American Psychiatric Association, Washington, DC.
12. Kafka M. Axis I psychiatric disorders, paraphilic sexual offending and implications for pharmacological treatment. Isr J Psychiatry Relat Sci 2012, 49(4):255-261.
13. McConaghy N. Paedophilia: a review of the evidence. Australas Psychiatry 1998, 32(2):252-265.
14. Hall R.C., Hall R.C. A profile of pedophilia: definition, characteristics of offenders, recidivism, treatment outcomes, and forensic issues. Mayo Clin Proc 2007, 82(4):457-471.
15. Murray J.B. Psychological profile of pedophiles and child molesters. JPsychology 2000, 134(2):211-224.
16. Turner D., Basdekis-Jozsa R., Dekker A., et al. Which factors influence the appropriateness of testosterone-lowering medications for sex offenders? A survey among clinicians from German forensic-psychiatric institutions. World J Biol Psychiatry 2013, 1-7. [Epub ahead of print].
17. McGrath R.J., Cumming G.F., Burchard B.L., et al. Current practices and emerging trends in sexual abuser management. The Safer Society North American Survey 2009, Vol 1:1-141. Safer Society Press, Brandon, Vermont.
18. Meston C.M., Frohlich P.F. The neurobiology of sexual function. Arch Gen Psychiatry 2000, 57(11):1012.
19. Waldinger M.D., Berendsen H.H., Blok B.F., et al. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998, 92(2):111-118.
20. Virkkunen M., De Jong J., Bartko J., et al. Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters: a follow-up study. Arch Gen Psychiatry 1989, 46(7):600.
21. Virkkunen M., Rawlings R., Tokola R., et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994, 51(1):20.
22. Maes M., van West D., De Vos N., et al. Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia. Neuropsychopharmacology 2001, 24(1):37-46.
23. Adi Y., Ashcroft D., Browne K., et al. Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technol Assess 2002, 57:1012-1030.
24. Stein D.J., Hollander E., Anthony D.T., et al. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. JClin Psychiatry 1992, 53(8):267-271.
25. Bradford J, Greenberg D, Gojer J, etal. Sertraline in the treatment of pedophilia: an open label study. Paper presented at the 148th annual meeting of the American Psychiatric Association, Miami, FL, May 20-25, 1995.
26. Hansen H., Lykke-Olesen L. Treatment of dangerous sexual offenders in Denmark. JForensic Psychiatr 1997, 8(1):195-199.
27. Bradford J.M. The treatment of sexual deviation using a pharmacological approach. JSex Res 2000, 37(3):248-257.
28. 1B agonist effects on intermale aggression. Neurosci Biobehav Rev 1998, 23(2):325-336.
29. Rubinow D.R., Schmidt P.J. Androgens, brain, and behavior. Am J Psychiatry 1996, 153(8):974-984.
30. Rösler A., Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. NEngl J Med 1998, 338(7):416-422.
31. Thibaut F., Cordier B., Kuhn J.M. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 1993, 87(6):445-450.
32. Thibaut F., Cordier B., Kuhn J.M. Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment?. Psychoneuroendocrinology 1996, 21(4):411-419.
33. Thibaut F., Kuhn J., Cordier B., et al. Hormone treatment of sex offenses. Encephale 1998, 24(2):132. [in French].
34. Schober J.M., Kuhn P.J., Kovacs P.G., et al. Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav 2005, 34(6):691-705.
35. Moulier V., Fonteille V., Pélégrini-Issac M., et al. Apilot study of the effects of gonadotropin-releasing hormone agonist therapy on brain activation pattern in a man with pedophilia. Int J Offender Ther Comp Criminol 2012, 56(1):50-60.